Details of the Drug

General Information of Drug (ID: DMJSC07)

• Drug Name: Bufuralol
• Synonyms: Bufuralol; Bufuralol [BAN:INN]; Bufuralol [INN:BAN]; Bufuralolum; Bufuralolum [INN-Latin]; Ro 3-4787; dl-Bufuralol; (RS)-alpha-(tert-Butylamino)methyl)-7-ethyl-12-benzofuranmethanol; 1-(7-Ethylbenzofuran-2-yl)-2-tert-butylamino-1-hydroxyethane; 2-(tert-butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethanol; 2-(tert-butylamino)-1-(7-ethylbenzofuran-2-yl)ethanol; 54340-62-4; AC1L2GPJ; AC1Q777C; CHEBI:34593; CHEMBL296035; EINECS 259-112-5; GTPL9834; SCHEMBL78552; alpha-((tert-Butylamino)methyl)-7-ethyl-2-benzofuranmethanol

Indication

Disease Entry	ICD 11	Status	REF
Cardiac arrhythmias	BC9Z	Investigative	[1]

• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 261.36
  Topological Polar Surface Area (xlogp); 3.5
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  Clearance: The drug present in the plasma can be removed from the body at the rate of 8.9 mL/min/kg [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 2.3 hours [2]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.19% [2]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.7 L/kg [2]
• Chemical Identifiers:
  Formula: C16H23NO2
  IUPAC Name: 2-(tert-butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethanol
  Canonical SMILES: CCC1=CC=CC2=C1OC(=C2)C(CNC(C)(C)C)O
  InChI: SSEBTPPFLLCUMN-UHFFFAOYSA-N
  InChIKey: 1S/C16H23NO2/c1-5-11-7-6-8-12-9-14(19-15(11)12)13(18)10-17-16(2,3)4/h6-9,13,17-18H,5,10H2,1-4H3
• Cross-matching ID:
  PubChem CID: 71733
  ChEBI ID: CHEBI:34593
  CAS Number: 54340-62-4
  DrugBank ID: DB06726
  INTEDE ID: DR0241

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[3]

References

• [1] Pharmacodynamic and pharmacokinetic studies on bufuralol in man. Br J Clin Pharmacol. 1986 Nov;22(5):527-34.
• [2] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [3] Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo. Mol Pharmacol. 2015 Apr;87(4):733-9.
• [4] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [5] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [6] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [7] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [8] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [9] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [10] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [11] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [12] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [13] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.